Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

Matthew Krebs; Alexander Spira; Byoung Cho; Benjamin Besse; Jonathan Goldman; Pasi Janne; Zhiyong Ma; Aaron Mansfield; Anna Minchom; Sai-Hong Ou; Ravi Salgia; Zhijie Wang; Casilda Perez; Grace Gao; Joshua Curtin; Amy Roshak; Robert Schnepp; Meena Thayu; Roland Knoblauch; Chee Lee

doi:10.1200/JCO.2022.40.16_suppl.9008

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

Matthew Krebs, Alexander Spira, Byoung Cho, Benjamin Besse, Jonathan Goldman, Pasi Janne, Zhiyong Ma, Aaron Mansfield, Anna Minchom, Sai-Hong Ou, Ravi Salgia, Zhijie Wang, Casilda Perez, Grace Gao, Joshua Curtin, Amy Roshak, Robert Schnepp, Meena Thayu, Roland Knoblauch, Chee Lee

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	9008
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
DOIs	https://doi.org/10.1200/JCO.2022.40.16_suppl.9008
Publication status	Published - 1 Jun 2022

Access to Document

10.1200/JCO.2022.40.16_suppl.9008

Cite this

Krebs, M., Spira, A., Cho, B., Besse, B., Goldman, J., Janne, P., Ma, Z., Mansfield, A., Minchom, A., Ou, S.-H., Salgia, R., Wang, Z., Perez, C., Gao, G., Curtin, J., Roshak, A., Schnepp, R., Thayu, M., Knoblauch, R., & Lee, C. (2022). Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. Journal of Clinical Oncology, 40, 9008. https://doi.org/10.1200/JCO.2022.40.16_suppl.9008

@article{74e5c6eff10f4d31b481516c9ad94e51,

title = "Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.",

author = "Matthew Krebs and Alexander Spira and Byoung Cho and Benjamin Besse and Jonathan Goldman and Pasi Janne and Zhiyong Ma and Aaron Mansfield and Anna Minchom and Sai-Hong Ou and Ravi Salgia and Zhijie Wang and Casilda Perez and Grace Gao and Joshua Curtin and Amy Roshak and Robert Schnepp and Meena Thayu and Roland Knoblauch and Chee Lee",

year = "2022",

month = jun,

day = "1",

doi = "10.1200/JCO.2022.40.16_suppl.9008",

language = "English",

volume = "40",

pages = "9008",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

}

Krebs, M, Spira, A, Cho, B, Besse, B, Goldman, J, Janne, P, Ma, Z, Mansfield, A, Minchom, A, Ou, S-H, Salgia, R, Wang, Z, Perez, C, Gao, G, Curtin, J, Roshak, A, Schnepp, R, Thayu, M, Knoblauch, R & Lee, C 2022, 'Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.', Journal of Clinical Oncology, vol. 40, pp. 9008. https://doi.org/10.1200/JCO.2022.40.16_suppl.9008

TY - JOUR

T1 - Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

AU - Krebs, Matthew

AU - Spira, Alexander

AU - Cho, Byoung

AU - Besse, Benjamin

AU - Goldman, Jonathan

AU - Janne, Pasi

AU - Ma, Zhiyong

AU - Mansfield, Aaron

AU - Minchom, Anna

AU - Ou, Sai-Hong

AU - Salgia, Ravi

AU - Wang, Zhijie

AU - Perez, Casilda

AU - Gao, Grace

AU - Curtin, Joshua

AU - Roshak, Amy

AU - Schnepp, Robert

AU - Thayu, Meena

AU - Knoblauch, Roland

AU - Lee, Chee

PY - 2022/6/1

Y1 - 2022/6/1

U2 - 10.1200/JCO.2022.40.16_suppl.9008

DO - 10.1200/JCO.2022.40.16_suppl.9008

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

SP - 9008

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -